NCT03755466View on ClinicalTrials.gov

Examination of Efficacy and Safety of Baricitinib in RA Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2025

Conditions
Rheumatoid Arthritis
Interventions
DRUG

"Baricitinib, olumiant®"

To examine the effects of baricitinib in RA patients

DRUG

"Biologics"

To examine the effects of biologics in RA patients

DRUG

Tofacitinib 5 MG [Xeljanz]

To examine the effects of tofacitinib in RA patients

Trial Locations (1)

3908621

RECRUITING

Yukio Nakamura, Matsumoto

All Listed Sponsors
lead

Shinshu University

OTHER